Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis psoriasis melanoma cutaneous and peripheral T-cell lymphoma. The drug is currently undergoing Phase II trials.
This page contains content from the copyrighted Wikipedia article "Zanolimumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.